News for Novo Nordisk A/S (NVO)

**media[651772]**

Eli Lilly & Co. sees 60% sales increase for weight-loss drug in India, tapping into growing demand for anti-obesity solutions.

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world’s third-highest number of obese people. The US drugmaker sold 126 million rupees ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about 75 million rupees.

Eli Lilly & Co. sees 60% sales increase for weight-loss drug Mounjaro in India, tapping into growing market demand.

ORCL gains on strong cloud momentum, while NVO battles obesity headwinds and LIN leans on $10B backlog for growth.

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer...

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to find out why LLY stock is a Hold.

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

The governance reforms sparked by the firing of Novo Nordisk's CEO may be exactly the fix the company needed.

Market Analysis by covering: S&P 500, Novavax Inc, Sanofi ADR, Novo Nordisk A/S. Read 's Market Analysis on Investing.com

On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change as a response to competitive pressures and shareholder demands, but warn that without a strategic shift, challenges may persist. On May 16, Novo […]

On May 19, F5, Inc. (NASDAQ:FFIV) announced an enhanced partnership with Red Hat, the leading provider of open-source solutions, aimed at helping enterprises securely deploy and scale high-performance AI applications. The collaboration enables businesses to accelerate retrieval-augmented generation (RAG), model serving, and scalable data ingestion, fostering AI adoption without compromising security. AI deployment is surging, […]

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index declined by -4.3% in Q1 2025 due to a tariff war and a shift away from AI-related tech stocks. Amid the tech-led sell-off, the […]

**media[630862]**

Discover why Novo Nordisk A/S' undervalued shares present a buying opportunity, with strong sales growth, profitability, and expansion. Click for more on NVO stock.

Novo Nordisk CEO Lars Fruergaard Jorgensen steps down amid fierce weight-loss competition and share price decline, as the company seeks new leadership.

Market Analysis by covering: Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down